Our Research Grants
CureSHANK has dedicated more than $400,000 toward funding research grants in 2023-2024. These grants address some of the highest priority deficits in the translational research gap between basic SHANK3 science and successful clinical trials for individuals living with Phelan-McDermid syndrome (PMS). With continued financial support from our donors, CureSHANK plans to continue and increase our funding of these types of urgently needed research projects.
See our Funding Opportunities page for researchers for other sources of research grants.
The CURESHANK Research-to-cure grant: EPILEPSY ($250,000 total)
"Assessing the contribution of GABAergic neuron hypofunction to pathological network states in Phelan-McDermid Syndrome (PMS)"
Jordan S. Farrell, PhD
Boston Children's Hospital
Summary: Loss of the Shank3 gene in PMS disrupts brain activity in people with the condition, sometimes as seizures and often as subtler abnormal communication patterns between nerve cells. We think this is because Shank3 loss impairs the brain’s “brake” cells (GABAergic neurons) that keep neural activity in check. In mice, we will test whether losing Shank3 produces these abnormal brain rhythms and whether removing it only from the “brake” cells is enough to trigger seizures. The results will help to learn more about the underlying cellular mechanisms of PMS, assisting researchers to design more targeted therapies.
-
Shank3 is a key component of excitatory connections between neurons and is non-uniformly expressed in different cell types, which suggests varying contributions of Shank3 to function in complex neural circuits. Occasionally, brain circuits become hyperactive and neurons fire synchronously, giving rise to seizures. Loss of Shank3, which occurs in Phelan McDermid Syndrome (PMS), is a known cause of seizure disorders (i.e., epilepsy) but not all individuals who harbor mutations or deletions of this gene have seizures.
Nevertheless, we have identified that PMS, even in people without epilepsy, is very commonly associated with more subtle patterns of pathological brain activity, highlighting that this gene is crucial in keeping neural activity within a physiological range and the full spectrum of pathophysiology needs to be better understood. Both the subtle network changes and overt epileptic seizures may result from a unique sensitivity of inhibitory GABAergic cells to loss of Shank3. Since GABAergic cells determine which neurons fire and when, effectively putting the brakes on neural activity in precise ways, reduced function of this system is suggested to be a common cause of epilepsy that many causal gene mutations converge upon.
Using cutting-edge in vivo tools in transgenic mice, we will test whether loss of Shank3 results in abnormal brain oscillatory patterns, as seen in clinical populations, that are indicative of a poorly functioning GABAergic system. We will also remove Shank3 only in GABAergic neurons, which isolates the loss of function to the brakes of the network, while leaving the accelerator intact. We expect that this manipulation will manifest with clear seizure activity. Insights from these experiments will shed light on what aspects of neural circuits need restoration across the spectrum of pathological activity in Shank3- related disorders and narrows the scope of future therapies to more selective targets.
"Inhibitory circuits underlying epileptogenesis in Shank3-deficiency”
Nick Frost, MD/PhD
University of Utah
Summary: People with PMS-SHANK3 gene disruptions often have social difficulties, intellectual disability, and epilepsy, but it’s unclear how the SHANK3 disruptions leads to seizures. Our earlier work in mice showed overactive brain cells in the forebrain linked to faulty inhibitory “brake”. We now propose to build the first seizure-induction (kindling) model in Shank3-deficient mice to test whether these “brake” cells let activity spread too easily between brain regions important for cognition. The findings will pinpoint specific cell types that future therapies could target to normalize brain activity and reduce seizure risk.
-
Individuals with genetic disruptions affecting the autism risk gene SHANK3 display anormal social behavior, intellectual disability, and often suffer from epilepsy. It is largely unclear how Shank3 disruptions contribute to epilepsy. Patients with genetic disruptions in SHANK3 develop seizures at variable ages suggesting that Shank3-deficiency increases risk for acquired epilepsy. In our recent experiments, we have demonstrated that Shank3b mutant mice have abnormal neuronal activity in frontal cortex. Moreover, this elevated activity is spatially restricted to more superficial regions within the cortical microcircuit and is associated with abnormal activity of inhibitory neurons. The goal of this proposal is to investigate the hypothesis that the disrupted activity of somatostatin-expressing cortical inhibitory interneurons permits increased recruitment of prefrontal neurons in response to hippocampal inputs, which may contribute to the origination and propagation of seizure like activity.
While mice harboring mutations recapitulate changes in social behavior observed in humans, they do not demonstrate spontaneous seizures. The kindling model is a well characterized method for modeling acquired epilepsy in rodents. We propose to generate the first kindling model of epilepsy in Shank3-deficient animals to investigate how loss of Shank3 affects the propagation of hippocampal activity to the medial prefrontal cortex. We will first examine the question of whether Shank3-deficiency leads to faster kindling. We will then examine whether Shank3-deficiency alters the recruitment of prefrontal neurons in response to hippocampal inputs. Finally, we will examine the role of prefrontal interneurons in modulating the propagation of activity from the hippocampus to the prefrontal cortex. These experiments will identify specific cell populations that can be targeted for therapeutic interventions aimed at normalizing circuit function underlying abnormal behavior and epileptogenesis in individuals with Shank3 mutations.
The CURESHANK Research-to-cure grant: Developmental regression ($125,000 total)
Developmental regression is one of the most heartbreaking symptoms of Phelan-McDermid syndrome (PMS). Nearly all parents of children with PMS have watched helplessly as their child loses skills once mastered. Sometimes this happens gradually and sometimes abruptly; for some it seems triggered by a specific health event, while for others there is no discernible catalyst. It usually happens to younger children, but it can happen anytime during childhood. Occasionally, skills are almost fully restored, but much more commonly, many are never recovered.
-
Relatedly, for individuals living with Phelan-McDermid syndrome, learning new skills is often an ephemeral task: when new skills are acquired, skills previously mastered seem to recede. The presentation is often not unlike Alzheimer’s or senile dementia, but in a child whose brain has not already had decades to establish neural pathways. Some individuals with Phelan-McDermid syndrome no longer appear to even recognize their own family members as distinct from other people.
CureSHANK has committed $125,000 toward the Developmental Regression in Phelan-McDermid Syndrome Grant.
Current status: At present, CureSHANK is engaged in a landscape analysis of the extant research regarding developmental regression in PMS and identifying some specific areas for exploration.
To see the devastation of Developmental Regression in PMS, watch Darus’s Story.
research grant Co-Sponsorships
$40,000 to date
Autism Science Foundation
CureSHANK is helping sponsor two Autism Science Foundation (ASF) Profound Autism Pilot Grants. Most individuals with Phelan-McDermid syndrome are diagnosed with autism and are usually categorized as requiring very substantial support (“Level 3”). Research involving individuals with profound autism is therefore often of high interest to CureSHANK and to the PMS community.
-
Nearly all caregivers of individuals living with Phelan-McDermid syndrome (PMS) report that their loved ones experience sleep dysfunction, often severe enough to require regular medication, and at times very difficult to manage. Those with profound autism and intellectual disability, who also frequently experience sleep problems, have been excluded from autism sleep studies because of the difficulty in studying this population in a lab setting. With a guarantee that PMS patients will be included in the study, we provided $20,000 in funding towards ASF’s project Testing a Novel Device to Study Sleep at Home in Children with Profound Autism. This study, led by Dimitrios Mylonas, Ph.D. at Massachusetts General Hospital, is evaluating the efficacy of a novel device for measuring sleep (and sleep dysfunction) in severe autism at home.
-
Many living with Phelan-McDermid syndrome (PMS) experience neuropsychiatric regression, a phenomenon distinct from developmental regression, which can include catatonia, hyper aggression, and cognitive decline, usually around or after the onset of puberty. We partnered with the Phelan-McDermid Syndrome Foundation (PMSF) and ASF to fund a study led by Sheng-Nan Qiao, Ph.D. at Yale University Modeling Neuroinflammation and Neuropsychiatric Regression in Profound Autism. This is an animal-model study with mice that have a SHANK3 mutation associated with PMS.
Candid
CANDID (Consortium for Autism, Neurodevelopmental Disorders & DIgestive Diseases) is a multidisciplinary collaboration between patient advocacy groups, scientists, clinician, and research organizations that is focused on addressing the common occurrence of gastrointestinal dysfunction in individuals with neurodevelopmental disorders. PMS is no exception: GI issues are cited as a significant challenge by many caregivers of individuals with PMS.
-
CureSHANK was a co-sponsor of the CANDID) Conference in June 2022.
The CANDID conference was the beginning of an effort of scientific workgroups to bring GI issues in these vulnerable populations to the forefront of research so as to increase funding toward the development of new treatments and measures for these problems.